Pliant Therapeutics announced its third quarter 2026 financial results, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095, an integrin inhibitor targeting resistant solid tumors. The company also reported promising preclinical data from its selective integrin-mediated drug delivery platform, which enables targeted RNAi delivery to specific tissues like muscle. Leadership was strengthened with new appointments in medical and RNAi research roles. With $142.6 million in cash, Pliant expects to fund operations through mid-2028 and plans to share more data and development plans in the coming months.
Pliant Therapeutics reported $142.6 million in cash and plans to fund operations through mid-2028, providing context for its recent corporate update. For readers following the Health sector, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced US Health stocks, 23 rose and 124 fell. Notable movers include CTXR at USD 0.53 with an 11.19% gain and 84% sell activity, SMMT at USD 15.10 down 9.25% with 57% buy activity, and IBRX at USD 6.06 down 9.15% with 98% sell activity.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
